| dc.contributor.author | Veiga, Viviane C. | |
| dc.contributor.author | Prats, João A. G. G. | |
| dc.contributor.author | Farias, Danielle L. C. | |
| dc.contributor.author | Rosa, Regis G. | |
| dc.contributor.author | Dourado, Leticia K. | |
| dc.contributor.author | Zampieri, Fernando G. | |
| dc.contributor.author | Machado, Flávia R. | |
| dc.contributor.author | Lopes, Renato D. | |
| dc.contributor.author | Berwanger, Otavio | |
| dc.contributor.author | Azevedo, Luciano C. P. | |
| dc.contributor.author | Avezum, Álvaro | |
| dc.contributor.author | Lisboa, Thiago | |
| dc.contributor.author | Rojas, Salomón S. O. | |
| dc.contributor.author | Coelho, Juliana C. | |
| dc.contributor.author | Leite, Rodrigo T. | |
| dc.contributor.author | Carvalho, Júlio C. | |
| dc.contributor.author | Andrade, Luis E. C. | |
| dc.contributor.author | Sandes, Alex F. | |
| dc.contributor.author | Pintão, Maria C. T. | |
| dc.contributor.author | Castro Junior, Claudio G. | |
| dc.contributor.author | Santos, Sueli V. | |
| dc.contributor.author | de Almeida, Thiago M. L. | |
| dc.contributor.author | Costa, André N. | |
| dc.contributor.author | Gebara, Otávio C. E. | |
| dc.contributor.author | Freitas, Flávio G. Rezende de | |
| dc.contributor.author | Pacheco, Eduardo S. | |
| dc.contributor.author | Machado, David J. B. | |
| dc.contributor.author | Martin, Josiane | |
| dc.contributor.author | Conceição, Fábio G. | |
| dc.contributor.author | Siqueira, Suellen R. R. | |
| dc.contributor.author | Damiani, Lucas P. | |
| dc.contributor.author | Ishihara, Luciana M. | |
| dc.contributor.author | Schneider, Daniel | |
| dc.contributor.author | Souza, Denise de | |
| dc.contributor.author | Cavalcanti, Alexandre B. | |
| dc.contributor.author | Scheinberg, Phillip | |
| dc.date.accessioned | 2021-07-08T19:57:41Z | |
| dc.date.available | 2021-07-08T19:57:41Z | |
| dc.date.issued | 2021 | |
| dc.identifier.citation | VEIGA, V. C. et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ, v. 372, n. 84, jun. 2021. Disponível em: http://hdl.handle.net/11690/1780. Acesso em: 08 jul. 2021. | pt_BR |
| dc.identifier.uri | http://hdl.handle.net/11690/1780 | |
| dc.language.iso | en_US | pt_BR |
| dc.publisher | BMJ Publishing Group | pt_BR |
| dc.rights | Open Access | en |
| dc.subject | COVID-19 | pt_BR |
| dc.title | Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | pt_BR |
| dc.type | Artigo | pt_BR |